MA29489B1 - Utilisation de tfpi dans le traitement d'infections bacteriennes aigues - Google Patents

Utilisation de tfpi dans le traitement d'infections bacteriennes aigues

Info

Publication number
MA29489B1
MA29489B1 MA30427A MA30427A MA29489B1 MA 29489 B1 MA29489 B1 MA 29489B1 MA 30427 A MA30427 A MA 30427A MA 30427 A MA30427 A MA 30427A MA 29489 B1 MA29489 B1 MA 29489B1
Authority
MA
Morocco
Prior art keywords
tfpi
treating bacterial
acute infections
develop
analogue
Prior art date
Application number
MA30427A
Other languages
English (en)
Inventor
Stephen F Hardy
Yumin Dai
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29489B1 publication Critical patent/MA29489B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE DES MÉTHODES DE TRAITEMENT PROPHYLACTIQUE OU THÉRAPEUTIQUE D'UN PATIENT SUSCEPTIBLE DE DÉVELOPPER OU CHEZ QUI ON A DIAGNOSTIQUÉ UNE INFECTION BACTÉRIENNE AIGUË IMPLIQUANT L'ADMINISTRATION D'UN INHIBITEUR DE LA VOIE DU FACTEUR TISSULAIRE (TFPI) OU D'UN ANALOGUE DE TFPI DESTINÉ À DES PATIENTS SOUFFRANT DE CETTE AFFECTION OU SUSCEPTIBLES DE LA DÉVELOPPER. CES PROCÉDÉS CONSISTENT À UTILISER UNE INFUSION INTRAVEINEUSE CONTINUE DE TFPI OU D'UN ANALOGUE DE TFPI EN FAIBLES QUANTITÉS DE MANIÈRE À ÉVITER LES EFFETS SECONDAIRES
MA30427A 2005-05-06 2007-11-29 Utilisation de tfpi dans le traitement d'infections bacteriennes aigues MA29489B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67846505P 2005-05-06 2005-05-06

Publications (1)

Publication Number Publication Date
MA29489B1 true MA29489B1 (fr) 2008-05-02

Family

ID=37103012

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30427A MA29489B1 (fr) 2005-05-06 2007-11-29 Utilisation de tfpi dans le traitement d'infections bacteriennes aigues

Country Status (16)

Country Link
US (1) US20090214506A1 (fr)
EP (1) EP1877081A2 (fr)
JP (1) JP2008540460A (fr)
KR (1) KR20080017021A (fr)
CN (1) CN101400365A (fr)
AU (1) AU2006244053A1 (fr)
BR (1) BRPI0611049A2 (fr)
CA (1) CA2607293A1 (fr)
IL (1) IL187111A0 (fr)
MA (1) MA29489B1 (fr)
MX (1) MX2007013876A (fr)
NO (1) NO20076245L (fr)
RU (1) RU2007145202A (fr)
TN (1) TNSN07413A1 (fr)
WO (1) WO2006122139A2 (fr)
ZA (1) ZA200709520B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009129164A1 (fr) * 2008-04-15 2009-10-22 Novartis Ag Combinaisons pharmaceutiques de fragments de tfpi et d'un antibiotique
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3022228B1 (fr) 2013-07-19 2019-02-27 Novo Nordisk A/S Anticorps capables de se lier spécifiquement à la partie n-terminale de l'inhibiteur de la voie du facteur tissulaire (tfpi (1-79))
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105777875B (zh) * 2016-05-26 2020-02-11 青岛农业大学 一种抗菌肽cstc24及其应用
CN105777876B (zh) * 2016-05-26 2020-02-11 青岛农业大学 一种抗菌肽tc38及其应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11572295B1 (en) * 2019-06-11 2023-02-07 Swamp Fox Innovations, LLC Compositions and methods for reduction of free chlorine and related odor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200400548A1 (ru) * 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
WO2005019265A1 (fr) * 2003-08-13 2005-03-03 Chiron Corporation Procede ameliore de purification d'analogues tfpi et tfpi

Also Published As

Publication number Publication date
TNSN07413A1 (en) 2009-03-17
CA2607293A1 (fr) 2006-11-16
US20090214506A1 (en) 2009-08-27
MX2007013876A (es) 2008-04-02
BRPI0611049A2 (pt) 2010-08-10
RU2007145202A (ru) 2009-06-20
NO20076245L (no) 2007-12-06
ZA200709520B (en) 2008-11-26
KR20080017021A (ko) 2008-02-25
WO2006122139A3 (fr) 2007-04-26
JP2008540460A (ja) 2008-11-20
IL187111A0 (en) 2008-02-09
CN101400365A (zh) 2009-04-01
WO2006122139A2 (fr) 2006-11-16
EP1877081A2 (fr) 2008-01-16
AU2006244053A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
MA29489B1 (fr) Utilisation de tfpi dans le traitement d'infections bacteriennes aigues
MA31822B1 (fr) Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MA34002B1 (fr) Thérapie antivirale
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
EA200971053A1 (ru) Способы лечения кожных язв
PL2081435T3 (pl) Inhibitory kinazy tyrozynowej brutona
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
MX2008013635A (es) Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
WO2020186132A8 (fr) Traitement d'une crise d'angio-œdème héréditaire avec une dose réduite d'anticorps se liant à la kallicréine plasmatique humaine
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
EP1596868A4 (fr) Methode de traitement d'une insuffisance cardiaque grave et medicament associe
FR3032883B1 (fr) Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
MA63848B1 (fr) Méthodes de traitement d'une splénomégalie
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
WO2008016640A3 (fr) Traitement de l'insuffisance cardiaque progressive chronique
EP4027815A4 (fr) Compositions comprenant de la cytisine dans le traitement et/ou la prévention de l'addiction chez des sujets en ayant besoin
EP1749532A4 (fr) Médicament pour la guérison ou le traitement d'une blessure
EP2231148A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention d'une maladie cardiaque
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
EP2137156A4 (fr) Promédicaments biodisponibles par voie orale de (+)-3-hydroxymorphinane utilisés dans la prévention ou le traitement de la maladie de parkinson
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales